Cubist Cidecin review extended
Executive Summary
FDA extends June 20 priority review action date for Cubist's Cidecin (daptomycin) injection three months to Sept. 20. The extension follows reformatting of data sets, which FDA classified as a "major amendment." The company still expects to launch the product for treatment of complicated skin and skin structure infections by the end of 2003...